278 related articles for article (PubMed ID: 26519648)
1. Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.
Li J; Ai Y; Wang L; Bu P; Sharkey CC; Wu Q; Wun B; Roy S; Shen X; King MR
Biomaterials; 2016 Jan; 76():52-65. PubMed ID: 26519648
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of platelets to neutralize circulating tumor cells.
Li J; Sharkey CC; Wun B; Liesveld JL; King MR
J Control Release; 2016 Apr; 228():38-47. PubMed ID: 26921521
[TBL] [Abstract][Full Text] [Related]
3. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells.
Lu Y; Lian S; Ye Y; Yu T; Liang H; Cheng Y; Xie J; Zhu Y; Xie X; Yu S; Gao Y; Jia L
Pharmacol Res; 2019 Jan; 139():535-549. PubMed ID: 30366102
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles Coated with Neutrophil Membranes Can Effectively Treat Cancer Metastasis.
Kang T; Zhu Q; Wei D; Feng J; Yao J; Jiang T; Song Q; Wei X; Chen H; Gao X; Chen J
ACS Nano; 2017 Feb; 11(2):1397-1411. PubMed ID: 28075552
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy.
Smit DJ; Pantel K; Jücker M
Biochem Pharmacol; 2021 Jun; 188():114589. PubMed ID: 33932470
[TBL] [Abstract][Full Text] [Related]
6. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.
Mathenge EG; Dean CA; Clements D; Vaghar-Kashani A; Photopoulos S; Coyle KM; Giacomantonio M; Malueth B; Nunokawa A; Jordan J; Lewis JD; Gujar SA; Marcato P; Lee PW; Giacomantonio CA
Neoplasia; 2014 Nov; 16(11):950-60. PubMed ID: 25425969
[TBL] [Abstract][Full Text] [Related]
7. Platelet mediated TRAIL delivery for efficiently targeting circulating tumor cells.
Ortiz-Otero N; Marshall JR; Lash BW; King MR
Nanoscale Adv; 2020 Sep; 2(9):3942-3953. PubMed ID: 36132797
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.
Liu S; Zhang Y; Zhao X; Wang J; Di C; Zhao Y; Ji T; Cheng K; Wang Y; Chen L; Qi Y; Li S; Nie G
Nano Lett; 2019 Jul; 19(7):4721-4730. PubMed ID: 31180684
[TBL] [Abstract][Full Text] [Related]
9. The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis.
Shi Q; Ji T; Tang X; Guo W
Cell Oncol (Dordr); 2023 Jun; 46(3):521-532. PubMed ID: 36652166
[TBL] [Abstract][Full Text] [Related]
10. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers.
Da X; Mo J; Li Q; Cao B; Huang J; Lu Y; Lu L; Fan M; Lu H
Biochem Biophys Res Commun; 2023 Sep; 671():335-342. PubMed ID: 37327705
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of circulating tumor cells prevents metastasis and extends survival.
Kim YR; Yoo JK; Jeong CW; Choi JW
J Hematol Oncol; 2018 Sep; 11(1):114. PubMed ID: 30201021
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
13. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial.
Xie J; Dong H; Chen H; Zhao R; Sinko PJ; Shen W; Wang J; Lu Y; Yang X; Xie F; Jia L
J Nanobiotechnology; 2015 Feb; 13():9. PubMed ID: 25643843
[TBL] [Abstract][Full Text] [Related]
14. A Role of Effector CD
Mahasa KJ; Ouifki R; de Pillis L; Eladdadi A
Bull Math Biol; 2024 Jun; 86(8):89. PubMed ID: 38884815
[TBL] [Abstract][Full Text] [Related]
15. Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis.
Yang N; Jiang Y; Zhang H; Sun B; Hou C; Zheng J; Liu Y; Zuo P
Mol Pharm; 2015 Jan; 12(1):232-9. PubMed ID: 25418453
[TBL] [Abstract][Full Text] [Related]
16. Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.
Li J; Sharkey CC; Huang D; King MR
Cell Mol Bioeng; 2015; 8(1):137-150. PubMed ID: 25798204
[TBL] [Abstract][Full Text] [Related]
17. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
Tokudome N; Ito Y; Takahashi S; Kobayashi K; Taira S; Tsutsumi C; Oto M; Oba M; Inoue K; Kuwayama A; Masumura K; Nakayama Y; Watanabe C; Hatake K
Breast Cancer; 2011 Jul; 18(3):195-202. PubMed ID: 21465230
[TBL] [Abstract][Full Text] [Related]
18. Engineering Circulating Tumor Cells as Novel Cancer Theranostics.
Parkins KM; Dubois VP; Kelly JJ; Chen Y; Knier NN; Foster PJ; Ronald JA
Theranostics; 2020; 10(17):7925-7937. PubMed ID: 32685030
[TBL] [Abstract][Full Text] [Related]
19. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.
Kalykaki A; Agelaki S; Kallergi G; Xyrafas A; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):685-93. PubMed ID: 24493157
[TBL] [Abstract][Full Text] [Related]
20. Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes.
Lederman EE; Hope JM; King MR
Front Oncol; 2018; 8():410. PubMed ID: 30460191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
